Top

Published in:

01-10-2018 | Original Article

Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation

Authors: Feng Ni, Chang-you Yan, Sheng Zhou, Peng-yu Hui, Yong-hui Du, Liang Zheng, Jin Yu, Xiao-jian Hu, Zhi-gang Zhang

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2018

Abstract

Objective

The mainstay of treatment for advanced bladder cancer (BC) is cisplatin (CDDP)-based systematic chemotherapy. However, acquired chemoresistance induced by as yet unidentified mechanisms is encountered frequently and often results in treatment failure and disease progression. The present study was designed to elucidate the expression and potential role of the gene associated with retinoid-interferon-induced mortality-19 (GRIM19) in the pathogenesis of CDDP resistance in BC.

Methods

RT-qPCR and immunoblotting were employed to evaluate the expression profile of GRIM19 in clinical BC samples and in different BC cells. Using cell viability assay, apoptotic ELISA, xenografts mouse model, and Transwell assay, the effects of GRIM19 inhibition or GRIM19 overexpression on CDDP resistance were determined in different BC cells. Lastly, using co-immunoprecipitation, we provided the molecular evidence for the interaction between GRIM19 and Bcl-xL.

Results

Expression levels of GRIM19 were significantly down-regulated in recurrent BC specimens, and in experimentally induced CDDP-resistant BC cells. Functionally, overexpression of the exogenous GRIM19 potentiated CDDP sensitivity and suppressed the survival and invasion of BC cells in the presence of CDDP challenge. Mechanistically, the compromised CDDP chemosensitization induced by GRIM19 loss was at least partially attributed to the attenuation of Bcl-xL polyubiquitination and subsequent degradation, because (1) GRIM19 colocalized with Bcl-xL in the mitochondria of BC cells and (2) GRIM19 overexpression promoted the ubiquitination of Bcl-xL, and this event could be effectively reversed by pretreatment with inhibitors of p38-MAPK and JNK pathways, indicating that GRIM19 overexpression-induced Bcl-xL ubiquitination may achieve in a p38/JNK-dependent manner. Using the UMUC-3 cells stably depleted of endogenous GRIM19, we further show that inhibition of Bcl-xL rectified GRIM19 deficiency-caused CDDP resistance in BC cells. In addition, BCL2L1 mRNA levels were negatively correlated with GRIM19 mRNA levels in CDDP-associated clinical BC tissues.

Conclusions

Disruption of GRIM19/Bcl-xL is a key mechanism of CDDP resistance in advanced BC. Therapeutically, enhancement of GRIM19 expression or employment of p38/JNK inhibitors may serve as resensitizing therapies for subgroups of CDDP-resistant or refractory BC patients.

Available only for authorised users

Reulen RC, de Vogel S, Zhong W, Zhong Z, Xie LP, Hu Z, Deng Y, Yang K, Liang Y, Zeng X, Wong YC, Tam PC, Hemelt M, Zeegers MP (2017) Physical activity and risk of prostate and bladder cancer in China: the South and East China case-control study on prostate and bladder cancer. PLoS One 12(6):e0178613. https://doi.org/10.1371/journal.pone.0178613 (PONE-D-16-40674 [pii]) CrossRefPubMedPubMedCentral

Wang X, Zhang F, Wu XR (2017) Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin. Sci Rep 7:45983. https://doi.org/10.1038/srep45983 CrossRefPubMedPubMedCentral

Mitsui Y, Yasumoto H, Arichi N, Honda S, Shiina H, Igawa M (2012) Current chemotherapeutic strategies against bladder cancer. Int Urol Nephrol 44(2):431–441. https://doi.org/10.1007/s11255-011-0009-8 CrossRefPubMed

Kunze D, Erdmann K, Froehner M, Wirth MP, Fuessel S (2012) siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells. Anticancer Res 32(10):4313–4318PubMed

Mani J, Vallo S, Rakel S, Antonietti P, Gessler F, Blaheta R, Bartsch G, Michaelis M, Cinatl J, Haferkamp A, Kogel D (2015) Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (−)-Gossypol (AT-101). BMC Cancer 15:224. https://doi.org/10.1186/s12885-015-1239-4 CrossRefPubMedPubMedCentral

Moon du G, Lee SE, Oh MM, Lee SC, Jeong SJ, Hong SK, Yoon CY, Byun SS, Park HS, Cheon J (2014) NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol 45(3):1027–1035. https://doi.org/10.3892/ijo.2014.2505 CrossRefPubMedPubMedCentral

Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Hsieh CY, Pu YS (2000) Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines. Anticancer Res 20(5A):3221–3225PubMed

Wu N, Hui H, Cui L, Yang F (2017) GRIM-19 represses the proliferation and invasion of cutaneous squamous cell carcinoma cells associated with downregulation of STAT3 signaling. Biomed Pharmacother 95:1169–1176. https://doi.org/10.1016/j.biopha.2017.09.055 CrossRefPubMed

Moreira S, Correia M, Soares P, Maximo V (2011) GRIM-19 function in cancer development. Mitochondrion 11(5):693–699. https://doi.org/10.1016/j.mito.2011.05.011 CrossRefPubMed

10.

Huang Y, Yang M, Hu H, Zhao X, Bao L, Huang D, Song L, Li Y (2016) Mitochondrial GRIM-19 as a potential therapeutic target for STAT3-dependent carcinogenesis of gastric cancer. Oncotarget 7(27):41404–41420. https://doi.org/10.18632/oncotarget.9167 PubMedPubMedCentralCrossRef

11.

Yue X, Zhao P, Wu K, Huang J, Zhang W, Wu Y, Liang X, He X (2016) GRIM-19 inhibition induced autophagy through activation of ERK and HIF-1alpha not STAT3 in Hela cells. Tumour Biol 37 (7):9789–9796. https://doi.org/10.1007/s13277-016-4877-5 CrossRefPubMed

12.

Xie L, Zeng Y, Dai Z, He W, Ke H, Lin Q, Chen Y, Bu J, Lin D, Zheng M (2018) Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death. Int J Biol Sci 14 (5):577–585. https://doi.org/10.7150/ijbs.22220ijbsv14p0577 CrossRefPubMedPubMedCentral

13.

Ning P, Zhong JG, Jiang F, Zhang Y, Zhao J, Tian F, Li W (2016) Role of protein S in castration-resistant prostate cancer-like cells. Endocr Relat Cancer 23(8):595–607. https://doi.org/10.1530/ERC-16-0126 CrossRefPubMed

14.

Yu L, Su YS, Zhao J, Wang H, Li W (2013) Repression of NR4A1 by a chromatin modifier promotes docetaxel resistance in PC-3 human prostate cancer cells. FEBS Lett 587(16):2542–2551. https://doi.org/10.1016/j.febslet.2013.06.029 CrossRefPubMed

15.

Dong YS, Hou WG, Li Y, Liu DB, Hao GZ, Zhang HF, Li JC, Zhao J, Zhang S, Liang GB, Li W (2016) Unexpected requirement for a binding partner of the syntaxin family in phagocytosis by murine testicular Sertoli cells. Cell Death Differ 23(5):787–800. https://doi.org/10.1038/cdd.2015.139 CrossRefPubMed

16.

Zhang C, Lai JH, Hu B, Zhang S, Zhao J, Li W (2014) A chromatin modifier regulates Sertoli cell response to mono-(2-ethylhexyl) phthalate (MEHP) via tissue inhibitor of metalloproteinase 2 (TIMP2) signaling. Biochim Biophys Acta 1839(11):1170–1182. https://doi.org/10.1016/j.bbagrm.2014.08.006 CrossRefPubMed

17.

Li W, Wu ZQ, Zhao J, Guo SJ, Li Z, Feng X, Ma L, Zhang JS, Liu XP, Zhang YQ (2011) Transient protection from heat-stress induced apoptotic stimulation by metastasis-associated protein 1 in pachytene spermatocytes. PLoS One 6(10):e26013. https://doi.org/10.1371/journal.pone.0026013 (PONE-D-11-13839 [pii]) CrossRefPubMedPubMedCentral

18.

Guo S, Sun F, Guo Z, Li W, Alfano A, Chen H, Magyar CE, Huang J, Chai TC, Qiu S, Qiu Y (2011) Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. PLoS One 6(3):e17778. https://doi.org/10.1371/journal.pone.0017778 CrossRefPubMedPubMedCentral

19.

Yang C, Liu X, Yang F, Zhang W, Chen Z, Yan D, You Q, Wu X (2017) Mitochondrial phosphatase PGAM5 regulates Keap1-mediated Bcl-xL degradation and controls cardiomyocyte apoptosis driven by myocardial ischemia/reperfusion injury. In Vitro Cell Dev Biol Anim 53 (3):248–257. https://doi.org/10.1007/s11626-016-0105-2 CrossRefPubMed

20.

Han HM, Ko S, Cheong MJ, Bang JK, Seo CH, Luchian T, Park Y (2017) Myxinidin2 and myxinidin3 suppress inflammatory responses through STAT3 and MAPKs to promote wound healing. Oncotarget 8(50):87582–87597. https://doi.org/10.18632/oncotarget.20908 PubMedPubMedCentralCrossRef

21.

Cho YC, Kim YR, Kim BR, Bach TT, Cho S (2016) Thunbergia alata inhibits inflammatory responses through the inactivation of ERK and STAT3 in macrophages. Int J Mol Med 38(5):1596–1604. https://doi.org/10.3892/ijmm.2016.2746 CrossRefPubMed

22.

Park BH, Lim JE, Jeon HG, Seo SI, Lee HM, Choi HY, Jeon SS, Jeong BC (2016) Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2. Oncotarget 7(39):63870–63886. https://doi.org/10.18632/oncotarget.11563 CrossRefPubMedPubMedCentral

23.

Chen J, Solomides C, Parekh H, Simpkins F, Simpkins H (2015) Cisplatin resistance in human cervical, ovarian and lung cancer cells. Cancer Chemother Pharmacol 75(6):1217–1227. https://doi.org/10.1007/s00280-015-2739-2 CrossRefPubMed

24.

Chen F, Qin X, Xu G, Gou S, Jin X (2017) Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-kappaB pathways. Biochem Pharmacol 135:50–68. https://doi.org/10.1016/j.bcp.2017.03.004 CrossRefPubMed

25.

Liu Y, Chen X, Gu Y, Zhu L, Qian Y, Pei D, Zhang W, Shu Y (2015) FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway. Neoplasma 62(1):61–71CrossRefPubMed

26.

Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G (2014) Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 5:e1257. https://doi.org/10.1038/cddis.2013.428 CrossRefPubMedPubMedCentral

27.

Santin G, Piccolini VM, Barni S, Veneroni P, Giansanti V, Dal Bo V, Bernocchi G, Bottone MG (2013) Mitochondrial fusion: a mechanism of cisplatin-induced resistance in neuroblastoma cells? Neurotoxicology 34:51–60. https://doi.org/10.1016/j.neuro.2012.10.011 CrossRefPubMed

28.

Chappell NP, Teng PN, Hood BL, Wang G, Darcy KM, Hamilton CA, Maxwell GL, Conrads TP (2012) Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer. J Proteome Res 11(9):4605–4614. https://doi.org/10.1021/pr300403d CrossRefPubMed

29.

Nallar SC, Kalvakolanu DV (2017) GRIM-19: a master regulator of cytokine induced tumor suppression, metastasis and energy metabolism. Cytokine Growth Factor Rev 33:1–18. https://doi.org/10.1016/j.cytogfr.2016.09.001 CrossRefPubMed

30.

Zhang XY, Li M, Sun K, Chen XJ, Meng J, Wu L, Zhang P, Tong X, Jiang WW (2015) Decreased expression of GRIM-19 by DNA hypermethylation promotes aerobic glycolysis and cell proliferation in head and neck squamous cell carcinoma. Oncotarget 6(1):101–115. https://doi.org/10.18632/oncotarget.2684 PubMedCrossRef

31.

Cao F, Zhang Q, Chen W, Zheng F, Ran Q, He Y, Gao Y, Yao S (2017) miR-6743-5p, as a direct upstream regulator of GRIM-19, enhances proliferation and suppresses apoptosis in glioma cells. Biosci Rep. https://doi.org/10.1042/BSR20171038 CrossRefPubMedPubMedCentral

32.

Kong B, Wang Q, Fung E, Xue K, Tsang BK (2014) p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers. J Biol Chem 289(39):27134–27145. https://doi.org/10.1074/jbc.M114.594812 CrossRefPubMedPubMedCentral

33.

Cho HJ, Kim JK, Kim KD, Yoon HK, Cho MY, Park YP, Jeon JH, Lee ES, Byun SS, Lim HM, Song EY, Lim JS, Yoon DY, Lee HG, Choe YK (2006) Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. Cancer Lett 237(1):56–66. https://doi.org/10.1016/j.canlet.2005.05.039 CrossRefPubMed

34.

Schaaf A, Sagi S, Langbein S, Trojan L, Alken P, Michel MS (2004) Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol 22(3):188–192. https://doi.org/10.1016/j.urolonc.2004.01.010 CrossRefPubMed

35.

Kajihara R, Sakamoto H, Tanabe K, Takemoto K, Tasaki M, Ando Y, Inui S (2014) Protein phosphatase 6 controls BCR-induced apoptosis of WEHI-231 cells by regulating ubiquitination of Bcl-xL. J Immunol 192(12):5720–5729. https://doi.org/10.4049/jimmunol.1302643 CrossRefPubMed

36.

Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (5600):1911–1912. https://doi.org/10.1126/science.1072682 CrossRefPubMed

37.

Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE (2001) Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFkappaB, STAT and AP1 transcription factor families. Histol Histopathol 16(2):595–601. https://doi.org/10.14670/HH-16.595 PubMedCrossRef

38.

Tian N, Han Z, Li Z, Zhou M, Fan C (2014) Lin28/let-7/Bcl-xL pathway: the underlying mechanism of drug resistance in Hep3B cells. Oncol Rep 32(3):1050–1056. https://doi.org/10.3892/or.2014.3292 CrossRefPubMed

Title: Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation
Authors: Feng Ni
Chang-you Yan
Sheng Zhou
Peng-yu Hui
Yong-hui Du
Liang Zheng
Jin Yu
Xiao-jian Hu
Zhi-gang Zhang
Publication date: 01-10-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3651-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2018

Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1

Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer

A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors

A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2)

Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer

Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer